Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study

Fig. 3

Kaplan–Meier curves for progression-free survival. The median progression-free survival was 4.1 months (95% CI, 3.2–4.5) and 2.2 months (95% CI, 1.1–3.4) in the NPI or NIV groups, respectively (HR 0.51, 95% CI 0.36–0.71; p< 0.0001). Statistically significant differences were detected in the progression-free survival between groups. *The hazard ratio was calculated using a Cox proportional hazards model, with age, the sarcoma types, the number of metastatic sites, and the ECOG performance status as covariates and NPI or NIV therapy as the time-dependent factor

Back to article page